{
  "symbol": "DYN",
  "company": "Dyne Therapeutics, Inc.",
  "generated_at": "2026-06-24T07:36:47.285Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-10T00:16:49.967Z",
      "stage": "analyst",
      "outcome": "failed",
      "reason": null,
      "trigger": "[insider_cluster_universe] 4 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-10T00:16:49.941Z",
      "skip": true,
      "reason": "Score of 25 falls well below the 45 threshold. The dossier flags material anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with a ~$140M/quarter burn rate, create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.",
      "score": 25,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 18,
        "mispricing": 0,
        "quality": 5,
        "technical": 2
      },
      "debug_path": "drafts/2026-06-10-DYN.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-10T00:15:19.930Z",
      "summary": "Dyne is a clinical-stage neuromuscular biotech whose BLA submission on May 26 triggered the investigation's smart-money trigger. Director Brian Posner made two verified open-market P-code purchases totaling ~$70K at $18.21 and $16.94 in late May/early June — genuinely clustered within 14 days. Three other directors received stock-option grants (vesting 2027) on June 5, which are compensation instruments, not directional signals. The company has two near-term catalysts: z-rostudirsen BLA filed for DMD accelerated approval (decision expected Q1 2027), and ACHIEVE REC topline data due Q1 2027 for DM1. Valuation is binary-biased by definition — no FCF, pre-revenue — but the analyst consensus target of $38 implies ~114% upside from current levels. The main risk: share count was just doubled (200M→400M authorized) suggesting anticipated ATM dilution ahead of launch costs.",
      "verdict": "promising",
      "confidence": 4,
      "tool_calls": 23,
      "walltime_min": 17,
      "debug_path": "dossiers/2026-06-09-DYN.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "DYN",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (63.4%)",
      "rsi_neutral": "0 (60.4)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (6d ago)",
      "from_high": "0 (-16.6%)"
    },
    "summary": "BUY (score +7) · 12-1 mom 63.4% · RSI 60.4 · above_both · -16.6% from high",
    "last_close": 20.26,
    "one_month_ago_close": 17.37,
    "twelve_month_ago_close": 10.63,
    "twelve_one_momentum_pct": 63.41,
    "rsi_14": 60.4,
    "ma_stack": "above_both",
    "from_period_high_pct": -16.59,
    "period_high": 24.29,
    "price_targets": {
      "bear": 17,
      "fair": 25.62,
      "bull": 50,
      "bear_return_pct": -16.1,
      "fair_return_pct": 26.5,
      "bull_return_pct": 146.8,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 17,
        "target_mean": 38.25,
        "target_high": 50,
        "analyst_count": 16
      }
    },
    "generated_at": "2026-06-24T07:36:47.283Z"
  }
}